Premium
Islet Cell Antibodies and Insulin Autoantibodies in Patients Treated with Oral Hypoglycaemic Agents
Author(s) -
Jennings A.M.,
Spencer K.M.,
Dean B.M.,
Wilson R.M.,
Bottazzo G.F.,
Ward J.D.
Publication year - 1989
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1989.tb01200.x
Subject(s) - medicine , diabetes mellitus , autoantibody , insulin , type 2 diabetes , endocrinology , type 1 diabetes , antibody , islet , immunology
Clinical and immunological features suggesting Type 1 diabetes were assessed in 202 patients treated with oral hypoglycaemic agents for presumed Type 2 diabetes. Islet cell antibodies (ICA) were detected at a level exceeding 5 JDF units in 5.9 % of patients, and complement‐fixing ICA were detected in 3.4 %. IgG insulin autoantibodies were detected in 8.8 % of insulin‐naive patients, none of whom were ICA positive. ICA were detected more frequently in patients with shorter duration of diabetes ( p = 0.02). Age and relative body weight were similar in ICA positive and negative groups. ICA positive patients were more likely to have lost weight ( p < 0.02) than ICA negative patients, although this may have been attributable to the differing duration of diabetes in the two groups. Other individual clinical features suggesting Type 1 diabetes were not significantly more frequent in ICA positive patients. However, a higher proportion of ICA positive than ICA negative patients had one or more features suggestive of Type 1 diabetes irrespective of the duration of diabetes. Clinical features suggesting Type 2 diabetes were present in a similar proportion of ICA positive and ICA negative patients. Fasting and glucagon stimulated C‐peptide levels were similar in ICA positive and matched ICA negative patients.